Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis

Fig. 1

Price drop in value and rate for ten innovative anticancer drugs. Notes: Only ten drugs are included because the price of pazopanib and ibrutinib before the MIAN policy was not available. Each of the four drugs, i.e., octreotide, nilotinib, afatinib, and axitinib, has two different specifications. Left: value in US$ of drug price drop. Right: percentage change of price drop

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us